Latest breakthroughs in cancer research, treatment, and prevention
606 artigos
Researchers uncover how cancer cells evade ADC therapy by suppressing drug uptake — and identify a drug target to reverse resistance.
Mechanical tension in the tumor microenvironment controls iron metabolism and cell death susceptibility via a novel NCOA4-FTH1 autophagy axis.
Scientists identify how the HMBOX1-HACE1-ATG5 axis suppresses autophagy to restore 5-FU chemosensitivity in colorectal cancer.
A randomized trial shows hydroxychloroquine and everolimus can dramatically reduce dormant tumor cells in breast cancer survivors, potentially preventing relapse.
A pyruvate metabolism enzyme suppresses leucine catabolism to keep mTOR active in liver cancer — and blocking it shrinks tumors in vivo.
A first-in-human Phase 1 trial evaluates PF-07257876, a dual-checkpoint bispecific antibody targeting both CD47 and PD-L1, in hard-to-treat cancers.
A Phase II NCI trial testing bintrafusp alfa in metastatic urothelial carcinoma was terminated after enrolling only 2 patients.
A bespoke DNA vaccine tailored to individual glioblastoma tumors shows promising immunological activity in one of oncology's hardest challenges.
Blocking CysLTR1 reprograms immunosuppressive neutrophils and reverses resistance to anti-PD1 checkpoint therapy in mice.
A newly identified lipid mediator may explain why immune cells fail to fight MASH-driven liver cancer, opening therapeutic targets.
MAIT cells appear to provide protective immune surveillance in Lynch syndrome carriers who haven't developed colorectal cancer, suggesting new risk stratification tools.
A comprehensive review in CA Cancer J Clin maps the molecular biology, treatment strategies, and equity gaps in high-grade serous ovarian cancer.
